64380-24-1

Basic information

• Product Name: 3-(trifluoromethyl)cinnamide
• Synonyms: 3-(trifluoromethyl)cinnamide
• CAS NO: 64380-24-1
• Molecular Formula: C₁₀H₈F₃NO
• Molecular Weight: 215.17
• Mol File: 64380-24-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 347.8°C at 760 mmHg
• Flash Point: 164.2°C
• Appearance: /
• Density: 1.306g/cm³
• Vapor Pressure: 5.25E-05mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: 3-(trifluoromethyl)cinnamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(trifluoromethyl)cinnamide(64380-24-1)
• EPA Substance Registry System: 3-(trifluoromethyl)cinnamide(64380-24-1)

Safety Data

• Hazardous Substances Data: 64380-24-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H8F3NO/c11-10(12,13)8-3-1-2-7(6-8)4-5-9(14)15/h1-6H,(H2,14,15)/b5-4+

Upstream product

• 779-89-5 3-(trifluoromethyl)cinnamic acid 
• 401-81-0 m-trifluoromethylphenyl iodide 
• 79-06-1 2-propenamide 
• 60689-14-7 trans-3-(trifluoromethyl)cinnamoyl chloride 

Downstream Products

• 535-53-5 3-(3-trifluoromethyl-phenyl)-propionic acid amide 
• 47230-38-6 diethyl biphenyl-4,4'-dicarboxylate 
• 58177-64-3 (E)-3-(3-(trifluoromethyl)phenyl)acrylonitrile 
• 802918-36-1 [(R)-1-(5,6-Dihydro-naphthalen-1-yl)-ethyl]-[3-(3-trifluoromethyl-phenyl)-propyl]-amine 
• 802918-36-1 [(S)-1-(5,6-Dihydro-naphthalen-1-yl)-ethyl]-[3-(3-trifluoromethyl-phenyl)-propyl]-amine 
• 802918-46-3 [1-(7,8-dihydro-naphthalen-1-yl)-ethyl]-[3-(3-trifluoromethyl-phenyl)-propyl]-amine 
• 802918-47-4 [1-(5,6-dihydronaphthalen-1-yl)ethyl]-[3-(3-trifluoromethylphenyl)propyl]amine 
• 104774-87-0 3‐[3‐(trifluoromethyl)phenyl]propan‐1‐amine 

Relevant articles and documents

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis

The present invention relates to novel dihydronaphthalene compounds, compositions, methods for using the same, and processes for preparing the same. The present invention also relates to novel total synthesis approaches for preparing these compounds. In addition, the present invention relates to methods of producing quantities of isomers of these compounds and separating and purifying them using chiral separation techniques. The present invention also relates to methods of producing quantities of a single isometric compound without the need for chiral separation techniques.

Synthesis of Cinacalcet congeners

Two related substances 1 and 2 of Cinacalet were prepared. Two racemic isomeric dihydronaphthalenes 1 and 2 were prepared from commercially available 5-hydroxytetralone in five linear steps. A key palladium-catalyzed double bond migration led to the synthesis of both isomers from the same starting material. Preparative chiral HPLC separation provided the enantiomerically pure materials. An asymmetric synthesis employing CBS reduction to furnish 1 was also developed.